Entry Point Capital, LLC Roivant Sciences Ltd. Transaction History
Entry Point Capital, LLC
- $246 Million
- Q3 2025
A detailed history of Entry Point Capital, LLC transactions in Roivant Sciences Ltd. stock. As of the latest transaction made, Entry Point Capital, LLC holds 12,382 shares of ROIV stock, worth $251,230. This represents 0.08% of its overall portfolio holdings.
Number of Shares
12,382
Previous 11,419
8.43%
Holding current value
$251,230
Previous $128,000
46.09%
% of portfolio
0.08%
Previous 0.07%
Shares
7 transactions
Others Institutions Holding ROIV
# of Institutions
375Shares Held
436MCall Options Held
6.03MPut Options Held
2.52M-
Morgan Stanley New York, NY44.3MShares$899 Million0.04% of portfolio
-
Sb Investment Advisers (Uk) LTD London, X040.3MShares$818 Million4.61% of portfolio
-
Vanguard Group Inc Valley Forge, PA38.8MShares$787 Million0.01% of portfolio
-
Black Rock Inc. New York, NY35.4MShares$718 Million0.01% of portfolio
-
Qvt Financial LP New York, NY29.4MShares$596 Million36.4% of portfolio
About Roivant Sciences Ltd.
- Ticker ROIV
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 704,382,976
- Market Cap $14.3B
- Description
- Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne...